AMF Tjanstepension AB Acquires New Position in Stryker Co. (NYSE:SYK)

AMF Tjanstepension AB acquired a new stake in Stryker Co. (NYSE:SYK) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 4,154 shares of the medical technology company’s stock, valued at approximately $1,496,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. J. W. Coons Advisors LLC raised its stake in Stryker by 0.7% in the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock valued at $1,315,000 after acquiring an additional 26 shares during the period. Opal Wealth Advisors LLC raised its stake in Stryker by 1.6% in the 4th quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after acquiring an additional 28 shares during the period. Lindbrook Capital LLC raised its stake in Stryker by 2.0% in the 4th quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after acquiring an additional 28 shares during the period. Alhambra Investment Management LLC raised its stake in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after acquiring an additional 29 shares during the period. Finally, JFS Wealth Advisors LLC raised its stake in Stryker by 4.4% in the 4th quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company’s stock valued at $247,000 after acquiring an additional 29 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK stock opened at $379.28 on Friday. The stock has a fifty day moving average of $382.45 and a 200 day moving average of $372.99. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market capitalization of $144.73 billion, a price-to-earnings ratio of 48.88, a PEG ratio of 2.93 and a beta of 0.95. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Analysts Set New Price Targets

SYK has been the topic of several analyst reports. Citigroup reiterated a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Barclays upped their price target on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Wells Fargo & Company upped their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.